Table 1 Characteristics and quality of included studies
Studya, year | Location | Design | IOL | No. of patients/eyes | Longest follow up (month) | Jadad | Newcastle-Ottawa Scale |
|---|---|---|---|---|---|---|---|
Cochener, 2018 [9] | France | RCT | Symfony PanOptix FineVison | 20/40 20/40 20/40 | 6 | Randomization 1 Blindness 1 Dropouts 1 | – |
Mencucci, 2018 [10] | Italy | NRCS | Symfony PanOptix Lisa tri 839MP | 20/40 20/40 20/40 | 3 | – | Selection 3 Comparability 2 Outcome 2 |
AMO, 2017 [24] | United States | RCT | Symfony ZCB00 | 148/296 151/302 | 6 | Randomization 1 Blindness 2 Dropouts 1 | – |
Escandón-García, 2018 [18] | Portugal | NRCS | Symfony PanOptix FineVison | 15/30 7/14 23/46 | 3 | – | Selection 3 Comparability 1 Outcome 2 |
Monaco, 2017 [19] | Italy | RCT | Symfony PanOptix SN60WF | 20/40 20/40 20/40 | 4 | Randomization 2 Blindness 1 Dropouts 1 | – |
Pedrotti, 2016 [20] | Italy | NRCS | Symfony ZCB00 | 25/50 15/30 | 3 | – | Selection 3 Comparability 2 Outcome 3 |
Pilger, 2018 [21] | Germany | NRCS | Symfony ZCB00 | 15/30 15/30 | 3 | – | Selection 3 Comparability 2 Outcome 3 |
Ruiz-Mesa, 2017 [22] | Spain | NRCS | Symfony FineVison | 20/40 20/40 | 12 | – | Selection 3 Comparability 2 Outcome 2 |
Ruiz-Mesa, 2018 [23] | Spain | NRCS | Symfony PanOptix | 14/28 20/40 | 29 | – | Selection 2 Comparability 2 Outcome 2 |